Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market to reach US$29.47bn
24 September 2026.
Visiongain has released its new Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2026-2036, forecasting that the global market will grow from US$12.46 billion in 2026 to US$29.47 billion by 2036.
The market is forecast to expand at a compound annual growth rate (CAGR) of 9.0% between 2026 and 2036, driven by rising AMD prevalence in ageing populations, accelerating adoption of longer-acting anti-VEGF therapies, and expanding investment in next-generation treatment modalities including complement inhibitors, gene therapies, and sustained-release biologic platforms.
Key Market Growth Drivers & Industry Transformations
The global retinal diseases drugs market is entering a new phase of innovation as manufacturers focus on extending treatment durability, improving patient convenience, and expanding therapeutic options beyond conventional anti-VEGF monotherapy. Visiongain’s research identifies four key catalysts driving market expansion:
- Rising AMD Prevalence in Ageing Populations:Â AMD is strongly associated with ageing, with prevalence rising sharply after 60 and advanced forms occurring more frequently in individuals aged over 75. The global population aged 60 and above is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050, with AMD-related vision impairment cases projected to reach 21.34 million globally by 2050. AMD management is not episodic – patients require continuous monitoring, imaging, and repeated treatment, supporting recurring revenue generation across anti-VEGF drugs, complement pathway inhibitors, and emerging retinal therapies.
- Longer-Acting and Extended-Dosing Therapies Reshaping the Market:Â The most recent milestone came on 2 April 2026, when the FDA approved EYLEA HD (aflibercept) as the first injectable anti-VEGF therapy for wet AMD and diabetic macular oedema with dosing intervals of up to five months. Next-generation candidates are pushing durability further: EyePoint’s EYP-1901, in global Phase III trials, is designed to deliver controlled drug levels for at least six months after a single administration, with Phase II data showing 63% of patients required no supplemental aflibercept over six months.
- Increasing Healthcare Expenditure on Vision Preservation:Â The International Agency for the Prevention of Blindness estimates that productivity losses linked to blindness and vision impairment amount to approximately US$411 billion annually worldwide. Governments and healthcare organisations are expanding investment in screening programmes, specialist eye-care services, and integrated ophthalmic treatment pathways, strengthening the commercial environment for advanced retinal therapeutics over the forecast period.
- Expansion of Next-Generation Drug Modalities:Â The retinal treatment landscape is evolving beyond anti-VEGF monotherapy toward bispecific antibodies, complement inhibitors, RNA-based therapeutics, gene therapies, encapsulated cell therapies, and sustained-release platforms. Innovation in retinal drug-delivery technologies is creating opportunities for more precise and less invasive treatment, with development activity focused on suprachoroidal delivery, hydrogel implants, microneedle-enabled ocular delivery, and non-viral gene-delivery platforms.
What This Means for the Retinal Diseases Drugs Market
The retinal diseases drugs market is transitioning from a single-modality anti-VEGF market into a multi-modality competitive landscape where treatment durability, delivery innovation, and disease-modifying capability are determining commercial positioning. Companies with diversified retinal portfolios, robust clinical pipelines, and differentiated delivery technologies are likely to strengthen their competitive position as healthcare providers increasingly prioritise therapies that combine sustained efficacy, improved patient adherence, and long-term value. Biosimilar entry is simultaneously improving treatment accessibility and intensifying pricing competition in mature markets, while the unmet need in dry AMD and geographic atrophy is attracting significant pipeline investment that will shape market dynamics across the second half of the forecast period.
Executive Quote
“The global retinal diseases drugs market is entering a new competitive phase where treatment durability, novel delivery technologies, and disease-modifying approaches are becoming the primary drivers of commercial differentiation,” stated a Senior Pharma Analyst at Visiongain.
“Over the next decade, companies that combine longer-acting biologics with next-generation modalities and personalised delivery strategies will be best positioned to capture value as the market expands well beyond conventional anti-VEGF therapy.”
Scope of the Visiongain Report
The 340+ page report provides robust quantitative and qualitative analysis across all key facets of the global market:
- By Disease Indication:Â AMD; Diabetic Macular Edema; Diabetic Retinopathy; Retinal Vein Occlusion; Others.
- By Route of Administration:Â Intravitreal; Others.
- By Drug Type:Â Branded Drugs (Eylea, Lucentis, Vabysmo, Others); Biosimilar Drugs.
- By Treatment Type:Â Anti-VEGF Agents; Complement Pathway Inhibitors; Gene & Cell Therapies; Dietary Supplements and Antioxidants; Others.
- By End User:Â Hospitals; Ambulatory Surgical Centres; Speciality Clinics; Diagnostic Imaging Centres; Others.
- By Regional & Country Markets:Â North America, Europe, Asia Pacific, Latin America, and MEA.
Competitive Landscape
The competitive environment is characterised by large pharmaceutical companies advancing extended-dosing programmes, specialist ophthalmology developers investing in complement and gene therapy pipelines, and biosimilar manufacturers intensifying pricing competition in mature anti-VEGF markets. Major market participants evaluated in the report include:
- Astellas Pharma
- Bayer AG
- Biocon
- Biogen
- Chengdu Kanghong Biotech
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Intas Pharmaceuticals
- Kodiak Sciences
- Novartis AG
- Ocular Therapeutix
- Outlook Therapeutics
- Regeneron Pharmaceuticals
- Sandoz Group AG
- STADA Arzneimittel AG
- Mighty Therapeutics
- Teva Pharmaceutical Industries
Recent Developments
- 18 Jun 2026 –Â Ocular Therapeutix reached alignment with the FDA on plans to submit an NDA for Axpaxli (OTX-TKI) for wet AMDÂ in Q4 2026, based on efficacy and safety findings from the Phase 3 SOL-1 trial and interim safety data from the ongoing SOL-R study.
- 16 Jun 2026 –Â Outlook Therapeutics announced FDA acknowledgement of the resubmission of its BLA for ONS-5010/LYTENAVAÂ for the treatment of neovascular age-related macular degeneration (wet AMD).
- 2 Apr 2026 – Regeneron announced FDA approval of extended dosing intervals for EYLEA HD (aflibercept) of up to every 20 weeks for patients with wet AMD and diabetic macular oedema following one year of successful response.
- 23 Feb 2026 –Â Sandoz confirmed European Commission marketing authorisation for Ranluspec, indicated for wet AMD, diabetic macular oedema, proliferative diabetic retinopathy, retinal vein occlusion, and choroidal neovascularisation.
Related Reports
Ophthalmic Drugs Market Report 2026-2036
Cell & Gene Therapy Manufacturing Market Report 2026-2036
About Visiongain
Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.
Media Contact
press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com
